Alight and eMed Join Forces to Expand Access to GLP-1 Therapies for Employers, Advancing Population and Workforce Health

Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugs

Despite its admirable goal, Medicare’s Bridge program risks could limit GLP-1 weight loss drug access by creating a complex, burdensome process.

Alight and eMed Join Forces to Expand Access to GLP-1 Therapies for Employers, Advancing Population and Workforce Health

DEERFIELD, Ill.--(BUSINESS WIRE)--Alight, Inc. (NYSE: ALIT), a leading benefits administration provider of health, wealth and leave solutions, today announced the addition of eMed Population Health, Inc., a platform for employer-sponsored preventative health management, to the Alight Partner Network. The collaboration will enhance employer-sponsored access to GLP-1 therapies and give organizations a scalable way to support more... The post Aligh…